C反応性タンパク質は,血管の滑らかな筋肉のアンジオテンシン1型受容体を上調する
Chao-Hung Wang1, Shu-Hong Li, Richard D Weisel
1Division of Cardiac Surgery, University of Toronto, Toronto, Ontario, Canada.
Circulation
|April 1, 2003
まとめ
C-反応性タンパク質 (CRP) は,血管の滑らかな筋肉細胞におけるアンジオテンシン1型受容体 (AT1-R) 発現を増加させることで,動脈硬化を促進します. AT1-Rブロッカーであるロサルタンは,これらのCRP誘発のプロアテロスクレロティック効果を in vitroおよびin vivoで弱めた.
科学分野:
- 心血管生物学 心血管生物学
- 炎症の研究 炎症の研究
- 分子医学は分子医学である.
背景:
- C反応性タンパク質 (CRP) は,血管疾患の進行に関与しています.
- CRPは,内皮細胞を活性化することによって,動脈硬化性病変の形成を積極的に促進する可能性があります.
- アンジオテンシン1型受容体 (AT1-R) は,動脈硬化症において重要な役割を果たします.
研究 の 目的:
- 血管滑らかな筋肉 (VSM) 細胞におけるAT1-R発現と運動学に対するCRPの影響を調査する.
- ローサルタンとローサルタンなしのVSMの移動,増殖,および活性酸素種 (ROS) 産生に対するCRPの影響を評価する.
- ネズミの carotid angioplastyモデルでネオインティマルの形成におけるCRPの役割を調査する.
主な方法:
- 培養ヒトVSM細胞におけるAT1-R mRNAとタンパク質に対するヒト再結合CRPの影響を研究した.
- VSMの移動,増殖,およびROSの生産を in vitroで評価した.
- ネズミの頸動脈の風船損傷モデルを利用して,neointimal形成を in vivo で研究しました.
主要な成果:
- CRPは,AT1-R mRNA,タンパク質発現,およびVSM細胞の細胞表面数を著しく上調した.
- CRPは,VSMの移動,増殖,ROSの産生を強化し,アンジオテンシンII効果を強化した.
- In vivoでは,CRPはネオインティマル形成,VSM移動,増殖,AT1-R発現を増加させ,ロサルタンにより効果が低下した.
結論:
- CRPは,血管の滑らかな筋肉細胞のAT1-R媒介性動脈硬化イベントを,インビトロとインビボの両方で上調する.
- CRPは,心血管リスクマーカーであることに加えて,前動脈硬化因子として作用します.
- これらの発見は,CRPに関連した心血管疾患におけるAT1-Rを標的とした治療の可能性を強調しています.
関連する概念動画
Adrenergic Receptors: ɑ Subtype
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenergic Receptors: β Subtype
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Antihypertensive Drugs: Action of β1 Blockers
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...


